Gemphire Therapeutics, Inc.
They are a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH.
Last Closing Price
February 8, 2018
To view the prospectus for Gemphire Therapeutics, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277